MiniMed Group, Inc. (MMED)
| Market Cap | 5.54B |
| Revenue (ttm) | 3.22B +15.7% |
| Net Income | -314.00M |
| EPS | -1.19 |
| Shares Out | 281.35M |
| PE Ratio | n/a |
| Forward PE | 31.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,695,065 |
| Open | 19.53 |
| Previous Close | 19.60 |
| Day's Range | 19.29 - 19.98 |
| 52-Week Range | 10.65 - 24.43 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 24.92 (+26.5%) |
| Est. Earnings | Nov 10, 2026 |
About MMED
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company’s platform includes Automated Insulin Delivery (AID) systems for... [Read more]
Financial Performance
In fiscal year 2026, MiniMed Group's revenue was $3.10 billion, an increase of 14.25% compared to the previous year's $2.72 billion. Losses were -$333.00 million, 56.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MMED stock is "Strong Buy." The 12-month stock price target is $24.92, which is an increase of 26.50% from the latest price.
News
Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure
The tax-free exchange offer allows Medtronic investors to swap their shares for MiniMed shares held by Medtronic in what Wall Street calls a split-off.
MiniMed names Sheila Denton as General Counsel & Corporate Secretary
MiniMed (MMED) announced that Sheila Denton has been named General Counsel & Corporate Secretary. Denton brings broad-ranging expertise in corporate governance, strategic transactions, intellectual pr...
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secreta...
MiniMed initiated with a Buy at Truist
Truist initiated coverage of MiniMed (MMED) with a Buy rating and $29 price target The company is near the final stage of its split-off from Medtronic (MDT), trading close to…
MiniMed Group Transcript: Bank of America Global Healthcare Conference
The company is accelerating growth with a robust innovation pipeline, including new launches like Flex and Fit, and a differentiated closed-loop algorithm, Vivera, targeting a 2027 launch. Strong commercial scale, disciplined financial management, and a stable, incentivized team underpin durable growth and expanding global presence.
MiniMed files S-4 in connection with Medtronic exchange offer
MiniMed (MMED) announced that it has filed a Form S-4 Registration Statement with the SEC in connection with Medtronic’s (MDT) offer to exchange up to 225,361,295 shares of MiniMed common…
Medtronic launches exchange offer to complete separation of MiniMed
Medtronic (MDT) announced that it has commenced an exchange offer to split off at least 80.1% of the shares of MiniMed Group (MMED). MiniMed, formerly Medtronic’s Diabetes business, completed its…
Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.
Medtronic shareholders can exchange their Medtronic ordinary shares for shares of MiniMed Provides Medtronic shareholders with option for a generally tax-free exchange for U.S. federal income tax pu...
MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement
NORTHRIDGE, Calif., Sept. 14, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) announced that it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in...
MiniMed Group Transcript: Wells Fargo 21st Annual Healthcare Conference
U.S. growth accelerated in Q1 due to new product launches, with Fit patch pump and Vivera algorithm set to expand the market, especially among Type 2 patients. Manufacturing and pharmacy strategies are in place to support upcoming launches, while international growth remains robust. Guidance and profitability targets are reaffirmed.
MiniMed Group Quarterly report: Q2 2026
MiniMed Group has published its Q2 2026 quarterly earnings report on September 8, 2026.
MiniMed price target raised to $21 from $19 at Morgan Stanley
Morgan Stanley raised the firm’s price target on MiniMed (MMED) to $21 from $19 and keeps an Overweight rating on the shares. The firm made “modest” adjustments to its model…
MiniMed price target raised to $25 from $20 at Deutsche Bank
Deutsche Bank raised the firm’s price target on MiniMed (MMED) to $25 from $20 and keeps a Buy rating on the shares.
MiniMed price target raised to $27 from $20 at Evercore ISI
Evercore ISI analyst Daniel Markowitz raised the firm’s price target on MiniMed (MMED) to $27 from $20 and keeps an Outperform rating on the shares.
MiniMed price target raised to $26 from $21 at Mizuho
Mizuho raised the firm’s price target on MiniMed (MMED) to $26 from $21 and keeps an Outperform rating on the shares following the fiscal Q1 report. With momentum from Flex…
MiniMed price target raised to $28 from $25 at UBS
UBS raised the firm’s price target on MiniMed (MMED) to $28 from $25 and keeps a Buy rating on the shares.
MiniMed price target raised to $28 from $25 at BTIG
BTIG raised the firm’s price target on MiniMed (MMED) to $28 from $25 and keeps a Buy rating on the shares. The firm is positive on the company’s better-than-expected Q1…
MiniMed price target raised to $28 from $24 at BofA
BofA raised the firm’s price target on MiniMed (MMED) to $28 from $24 and keeps a Buy rating on the shares. MiniMed delivered a “solid” fiscal Q1 beat, but pipeline…
MiniMed price target raised to $26 from $23 at Citi
Citi raised the firm’s price target on MiniMed (MMED) to $26 from $23 and keeps a Buy rating on the shares. The company reported better than expected fiscal Q1 results,…
MiniMed price target raised to $26 from $22 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised the firm’s price target on MiniMed (MMED) to $26 from $22 and keeps an Overweight rating on the shares. The company reported a Q1…
MiniMed jumps after upping fiscal 2027 organic growth outlook
Shares of MiniMed (MMED) are moving higher following the company’s fiscal Q1 earnings report. For fiscal 2027, MiniMed expects organic revenue growth of 10.5%, a raise from the prior guidance…
MiniMed Group Earnings Call Transcript: Q1 2027
Q1 delivered 16% organic revenue growth, driven by strong U.S. and international performance, new product launches, and expanding recurring revenue streams. Fiscal 2027 guidance was raised, with margin expansion expected as separation costs decline and new products ramp globally.
MiniMed Group Earnings release: Q1 2027
MiniMed Group released its Q1 2027 earnings on September 1, 2026, summarizing the period's financial results.